UCB (OTCMKTS:UCBJY) Cut to “Hold” at Zacks Research

UCB (OTCMKTS:UCBJY) was downgraded by stock analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report released on Monday,Zacks.com reports.

A number of other brokerages have also recently commented on UCBJY. The Goldman Sachs Group raised shares of UCB to a “strong-buy” rating in a research note on Wednesday, July 16th. Jefferies Financial Group upgraded UCB to a “moderate sell” rating in a report on Sunday, October 26th. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy”.

UCB Trading Up 1.8%

Shares of OTCMKTS UCBJY opened at $124.71 on Monday. The firm’s fifty day moving average is $131.91 and its two-hundred day moving average is $109.53. UCB has a 52-week low of $71.16 and a 52-week high of $151.76.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.